Through a combination of research and acquisitions, Ligand has created a partnered portfolio with a wide variety of underlying technologies. This diversification provides the added benefits of exposure to a wider variety of science, more licensing opportunities and lower impact of individual patent expiry.
Captisol® is a patent-protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).Licensing Contact
Three in-vivo platforms for the generation of mono- and bispecific therapeutic antibodies, OmniRat®, OmniMouse® and OmniFlic®, use patented technology, have broad freedom to operate and deliver fully human OmniAb® antibodies with high affinity, specificity, expression, solubility and stability.Licensing Contact
The SUREtechnology Platform™, a Selexis, SA technology, is based on novel DNA-based elements that control the dynamic organization of chromatin within mammalian cells and allow for higher and more stable expression of recombinant proteins. Several programs acquired by Ligand are based on this technology.